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Optimal HIV vaccines should elicit CD8 T cells specific for HIV
proteins presented on MHC class I products, because these T cells
contribute to host resistance to viruses. We had previously found
that the targeting of antigen to dendritic cells (DCs) in mice
efficiently induces CD8 T cell responses. To extend this finding to
humans, we introduced the HIV p24 gag protein into a mAb that
targets DEC-205/CD205, an endocytic receptor of DCs. We then
assessed cross-presentation, which is the processing of nonrepli-
cating internalized antigen onto MHC class I for recognition by
CD8 T cells. Low doses of DEC-gag, but not control Ig-gag,
stimulated proliferation and IFN- production by CD8 T cells
isolated from the blood of HIV-infected donors. CD205 fusion
mAb was more effective for cross-presentation than CD209/DC-
SIGN, another abundant DC uptake receptor. Presentation was
diverse, because we identified eight different gag peptides that
were recognized via DEC-205 in 11 individuals studied consecu-
tively. Our results, based on humans with highly polymorphic MHC
products, reveal that DCs and DEC-205 can cross-present several
different peptides from a single protein. Because of the consistency
in eliciting CD8 T cell responses, these data support the testing of
DEC-205 fusion mAb as a protein-based vaccine.
CD205, CD209  cross-presentation  DC-SIGN  vaccine
Resistance to HIV is in part mediated by CD8 T cells (1, 2),which recognize fragments of viral antigens presented on
MHC class I products (3). HIV-specific, CD8 T cells kill
virus-infected targets in culture (4, 5) and produce antiviral
chemokines (6, 7). CD8 T cells also resist immunodeficiency
viruses in vivo. In SIV-infected rhesus macaques, depletion of
CD8 T cells increases plasma viremia (8), including viremia due
to attenuated vaccines (9). HIV mutants that escape recognition
by CD8 T cells in vivo also become more pathogenic (10–12).
Therefore, effective protection against HIV will likely require
vaccines that elicit strong and broad CD8 T cell immunity.
Dendritic cells (DCs) are specialized antigen-presenting cells
that capture infectious agents and tumors and initiate CD8 T
cell immunity (13, 14). DCs express a number of cytokines and
membrane costimulators that drive the T cell response, and DCs
‘‘cross-present’’ antigens on MHC class I (15, 16). The cell
biology underlying cross-presentation is not yet fully defined
(17–19), but it allows DCs to extract peptides from nonreplicat-
ing internalized antigens for presentation to CD8 T cells. Such
peptides do not need to be synthesized in the DCs, but instead
‘‘cross’’ to their MHC I products from another source, e.g., from
select proteins (20–22), tumor cells (23–25), inactivated virus or
dying infected cells (26–28), immune complexes (29–31), and
self-tissues (32). In contrast, the classical pathway for presenta-
tion on MHC I is to generate peptides from proteins produced
during infection by replicating viruses (33, 34). The newly
synthesized proteins, probably made as defective ribosomal
initiation products (35), are degraded in the proteasome before
transport into the rough endoplasmic reticulum, where there is
binding of peptides to newly synthesized MHC I. In mice, DCs
are the major cell type capable of cross-presentation in vivo
(36–40). However, it has yet to be shown that DCs can cross-
present peptides across a spectrum of MHC haplotypes, an
essential requirement for protein-based vaccines in humans who
are highly polymorphic at the MHC or HLA locus.
A recent strategy to explore and harness DC biology for
vaccination is to target antigens to DCs in intact lymphoid organs
by incorporating specific antigens into anti-DC mAbs (41).
Among other advantages, the targeting of antigens in this way
enhances the efficiency of antigen presentation to CD4 and
CD8 T cells in vivo by 100-fold or more (41–44).
To extend these ideas to humans, we have selected a mAb to
human DEC-205/CD205 (45). In mice, DEC-205 mediates cross-
presentation (42–44). The receptor is also expressed on human
monocyte-derived DCs along with other endocytic receptors
(reviewed in ref. 46), such as the mannose receptor/CD206 and
DC-SIGN/CD209 (47, 48). A potential advantage of CD205 over
these other receptors is its high expression by DCs in the T cell
areas of lymph nodes in the steady state, whereas CD206 and
CD209 are abundant in macrophages in the medullary region of
lymph nodes (49). This finding means that CD205 mAb might
provide superior targeting of vaccine antigens to DCs in lym-
phoid tissues, where the DCs are ideally positioned to select
specific T cell clones from the repertoire. We now find that a
fusion CD205 mAb targets HIV gag for broad and efficient
cross-presentation in HIV-infected individuals. The data pro-
vide a rationale for further testing of this vaccine approach in
humans.
Results
Characterization of HIV gag Fusion mAbs. To deliver HIV antigens
to human DCs, we cloned HIV gag p24 protein in frame into the
carboxyl terminus of the heavy chain of mAbs to DEC-205,
DC-SIGN and MMR, which are endocytic receptors expressed
on monocyte-derived DCs; the heavy chain of an isotype-
matched control Ig was also engineered as a negative control
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[supporting information (SI) Fig. 5A]. The fusion mAbs were
produced by transient transfection in 293 T cells (1–2 mg/liter)
and purified from culture supernatants by protein G-affinity
chromatography. Purity was assessed after SDS/PAGE under
reducing conditions, by both Coomassie staining and Western
blot with a HRP-conjugated -mouse IgG. The fusion mAbs
were composed of a 75-kD heavy chain, as opposed to 50-kD
heavy chain of an unconjugated mouse IgG2b, the same isotype
as the DEC-205 and DC-SIGN mAbs (SI Fig. 5B). We also
verified the functional integrity of the mAbs by binding to
immature DCs, similar to that of the original unmodified mAbs
(Fig. 1).
Cross-Presentation of gag p24 Protein by DEC-205 Fusion mAb. To
study the ability of DEC p24 to mediate antigen presentation,
we added fusion mAb to blood cells from HIV-infected indi-
viduals and measured proliferation and IFN production by bulk
peripheral blood mononuclear cells (PBMCs) as well as cocul-
tures of monocyte-derived DCs and T cells. We examined cells
from treated chronically infected individuals as well as untreated
long-term nonprogressors. All were clinically stable and had
CD4 T cell counts of 400 per microliter. The T cells were
labeled with carboxyfluorescein succinimydl ester (CFSE) to
follow their proliferation by successive halving of the amount of
CFSE per cell with each division. Although we did not detect
responses by CD4 cells to gag antigen, the CD8 T cells
proliferated actively after stimulation with a pool of 55 peptides
spanning the HIV gag sequence and to a low dose of DEC p24
but not control Ig p24 (SI Fig. 6). The proliferating CD8 T cells
produced IFN if the cultures were rechallenged with p24
peptides for 6 h at the end of the 6- to 7-d expansion culture
(SI Fig. 6 and Fig. 2). Results from five individuals are shown in
Fig. 2 and indicate that the frequency of IFN CD8 CFSElow
T cells was greater after addition of the pool of gag peptides
relative to DEC p24. However, DEC p24 was reliably a more
efficient form of antigen than control Ig p24, which was com-
parable to the no-antigen or medium control. In each case, it was
necessary to restimulate the proliferated T cells with gag pep-
tides to detect their production of IFN (compare filled vs. open
symbols in Fig. 2). Higher frequencies of responding T cells were
noted in the DC–T cell cocultures than in bulk PBMCs (Fig. 2),
which may reflect either the greater numbers or improved
maturation of monocyte-derived DCs. Two seronegative donors
did not show responses to DEC p24 in these assays (data not
shown). Together, these results demonstrate that low concen-
trations of DEC p24 fusion mAb lead to antigen presentation
on MHC I, inducing consistent expansion of CD8 T cells
capable of producing IFN from HIV-infected donors.
DEC-205 Fusion mAb is Superior to DC-SIGN mAb for CD8 T Cell
Responses. To assess the consequences of targeting different
receptors, we compared DEC, MMR, and DC-SIGN p24
fusion mAbs. We found that DEC p24 was reliably more
effective than the other fusion mAbs in inducing proliferation
and IFN production from CD3CD8 cells in PBMCs (Fig. 3
and SI Fig. 7A). We made similar findings in a limited study of
Fig. 1. Binding of HIV gag p24 fusion mAbs to monocyte-derived DCs. Immature DCs were treated with 0.02, 0.2, and 2 g/ml of DEC p24, DC-SIGN p24, and
MMR p24 and with 2 g/ml control Ig p24. DCs were also treated with supernatant from each mAb clone as positive control and with nonreactive mAb as
negative control, followed by incubation with an -mIgG phycoerythrin-conjugated antibody.
Fig. 2. HIV gag p24-specific CD8 T cell responses to DECp 24. Summary of the frequencies of IFN-producing, proliferating, CD3CD8 T cells in response
to medium, p24 peptides, DEC p24, and control Ig p24 (1 g/ml), with or without restimulation at the end of the 6- to 7-day culture with p24 peptides.
Frequencies are shown for both PBMCs and cocultures of antigen-pulsed DCs and CFSE-labeled T cells.

































DC–T cell cocultures from four individuals (e.g., SI Fig. 7B).
These findings suggest that antigen delivery via DEC-205 is
superior to the other endocytic receptors for expanding gag-
specific CD8 T cells.
Broad CD8 T Cell Responses After DEC-205 Targeting. To document
which gag peptides were presented by DEC-205 targeting, we
studied 11 consecutive patients. All of them showed CD8 T cell
proliferation to the pool of HIV gag peptides and to the fusion
DEC p24 fusion mAb. Following expansion of the CFSE-
labeled T cells in response to DEC p24, we rechallenged the
cultures for 8 h with five pools of 15-mer overlapping peptides
that spanned the gag p24 sequence. In each donor, 1 or 2 pools
of peptides were recognized, but when different donors were
compared, all five pools could be recognized by one individual
or another (Table 1). By further breaking down the reactive
peptide pools, we found eight different ‘‘mimetope’’ peptides,
i.e., the 15-mer peptides that mimic the actual peptide naturally
processed by the DCs. Fig. 4 illustrates and Table 2 summarizes
the identification of diverse peptides that could be presented
from gag p24 by DEC-205 on DCs. The upper rows in Fig. 4 A–C
show the identification of the active peptide pool, and the lower
rows show the identification of the best peptide mimetope in the
pool. After HLA typing and consultation with the Los Alamos
database on known HIV gag peptides that are presented on
specific MHC I products, we were able to identify the likely
peptide sequences that were being presented after uptake,
processing, and cross-presentation of DEC p24. The data in
Tables 1 and 2 indicate that the targeting of gag within DEC-
205 mAb allows DCs from highly polymorphic human MHC I
products to cross-present at least 1 or 2 different peptides from
this small protein.
Discussion
Improved presentation of antigens by DCs offers the potential of
increased vaccine efficacy. DCs are potent inducers of T cell-
mediated immunity and memory and have the potential to
cross-present antigens from safe forms of vaccines to generate
protective CD8 T cells. Nevertheless, the prior literature on
cross-presentation has emphasized the study of single peptides
presented on single MHC I proteins. In mice, research is































Fig. 3. Comparison of CD8 T cell response after targeting of gag through different endocytic receptors. Frequency of IFN proliferating CD3 CD8 T cells
measured in CFSE-labeled PBMCs stimulated for 6 days with medium, p24 peptides at 2 g/ml and DEC p24, DC-SIGN p24, MMR p24, and control Ig p24, all
at 1 g/ml. All samples were restimulated for the last 6 h with p24 peptides.
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LB01 PBMC 0.02 3.1 1.4 0.25 0.34 1 0.38 0.29
LB01 DC/T 0.12 12 6.3 0.97 0.92 6.1 ND ND
LB02 PBMC 0.04 6.3 3.8 3.2 0.07 0.14 0.64 0.11
LB03 DC/T 0.04 17 2.6 0.54 0 2.0 0.88 0.03
LB04 PBMC 0.02 16 2.1 1.5 0.13 0.27 0.36 0.37
LB04 DC/T 1.52 34.7 43.3 33.7 1.51 5.87 1.58 4.02
LB05 DC/T 0.55 37.6 26.4 1.27 0.45 16.3 19.1 0.44
LB06 PBMC 0 9.73 6.09 1.8 1.38 4.94 1.8 1.58
Chronic
LB07exp1 PBMC 0.02 4.6 2.8 0.28 0.83 1.2 0.54 3.7
LB07 DC/T 0.23 11 3.4 1.2 1.5 3.9 1.4 4.4
LB07exp2 PBMC 0.17 3.9 1.7 0.25 0.14 0.61 0.36 1.3
LB08 DC/T 0.18 4.1 1.5 ND ND 0.21 0.46 1.7
LB09 PBMC 0.19 4.9 2.8 0.47 1.4 0.39 1.4 0.45
LB10 PBMC 0.022 1.28 1.22 0.09 1.42 0.09 0.09 0.05
LB10 DC/T 1.04 13.6 1.63 0.41 1.32 0.3 0.28 0.21
LB11 PBMC 0.006 10.6 5.96 0.39 5.22 0.55 1.06 0.57
Summary of the frequencies of IFN CFSE low CD8 cells obtained from either PBMCs or DC/T cell cocultures stimulated for 6–7 days with medium, p24
peptides, and DEC p24. The samples were then restimulated for 6–8 h with p24 peptides or with the individual peptide pools (see Materials and Methods). The
bold data represent pools of peptides that yield responses that are three times more than the background of nonstimulated cells. LTNP, long-term nonprogressor.









































on H-2Kb, in part because the binding of this peptide to MHC
class I is of such high affinity that it becomes easier to detect
cross-presentation. In humans, select peptides have been defined
that can be presented on HLA-A2.1, the MHC I molecule that
has dominated the literature.
Using the DEC-205/CD205 receptor to deliver antigens to
monocyte-derived DCs in vitro, we established that numerous
peptides from the HIV protein, gag p24, can be processed and
presented by DCs on many allelic forms of human MHC I. Our
data indicate that DEC-205 accesses the cross-presenting path-
way for many human HLA haplotypes.
Interestingly, antibodies to other receptors expressed on the
same DCs, DC-SIGN/CD209 or mannose receptor/CD206, were
less effective than CD205. All three mAbs bound comparably
to monocyte-derived DCs and were internalized by DCs (data
not shown), so we suspect that the DEC-205 receptor better
allows access to the cross-presentation pathway. This pathway
typically requires that portions of the gag protein gain access to
the cytoplasm, followed by proteosome-mediated degradation
and transport into the rough endoplasmic reticulum (reviewed in
refs. 18, 50, and 51). Another advantage of CD205 targeting is
that it is expressed on many DCs in the T cell areas of human
lymphoid tissues, whereas CD206 and CD209 are abundant on
macrophages in the lymph node medulla (49). This positioning
would allow the CD205-targeted vaccine to efficiently select
specific clones of T cells that recirculate from the blood through
lymphoid organs.
Although HIV-infected individuals exhibit CD4 T cell re-
sponses that were too weak for us to study here, other research
in mice shows that DEC-205 targeting is a powerful means for
inducing CD4 T cell immunity (43, 44) as well as antibody
responses (43). Together, the results with DEC-205 targeting
provide preclinical support to develop this strategy as a means
to induce strong T cell immunity in humans.
Materials and Methods
Patients. Peripheral blood (40–100 ml) was obtained from HIV-1
infected individuals who were recruited to the St. Vincent’s
Hospital Comprehensive Clinic and The Rockefeller University
Hospital according to institutional guidelines and after obtain-
ing informed consent. Patient information is summarized in SI
Table 3. Blood samples from two healthy seronegative subjects
were analyzed as negative controls.
Preparation of Dendritic Cells and T Cells. PBMCs were isolated
from heparinized blood on Ficoll density gradients. Monocytes
were enriched by using CD14 microbeads (Miltenyi Biotec,
Auburn, CA) and then cultured for 5 d with IL-4 (10 ng/ml) and
GM-CSF (100 units/ml) in RPMI 5% human serum to generate
immature DCs (52). The CD14 fraction was used as source of
A
B
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Fig. 4. Identification of mimetope peptides recognized by CD8 T cells in response to -DECp24. Results from patients LB04, LB06, and LB07 are shown in A–C,
respectively. CFSE-labeled cells were stimulated with medium or DEC p24 at 1 g/ml for 6–7 d, whereupon the cells were restimulated with five different pools
of gag peptides to detect IFN secretion from proliferated CFSElow, CD3CD8 T cells (Upper). The next day, parallel cultures were used to identify the individual
mimetope peptides from the reactive peptide pools (Lower).

































bulk T cells and cryopreserved in freezing medium (GIBCO)
before use.
Cloning and Production of Fusion HIV gag mAbs. mAbs for the
human receptors DEC-205, DC-SIGN, and MMR as well as a
control mAb to mouse I-Ak were cloned from total RNA from
the MG38.2 (45), 25B9G8 (49), 3.29 (47) (kindly provided by A.
Lanzavecchia, Bellinzona, Switzerland), and 10–2.16 (TIB93;
American Type Culture Collection, Manassas, VA) hybridomas.
The variable regions were produced with 5-RACE PCR kit
(GIBCO-BRL, Carlsbad, CA) by using primers for the 3 ends
of mouse IgG2b (DEC-205 and DC-SIGN mAbs) or mouse IgG1
(MMR), and Ig  (DEC-205) or Ig  (DC-SIGN, MMR). To
obtain full-length heavy and light chain Ig cDNA, the V regions
were cloned in-frame with a signal peptide and the respective
mouse Ig heavy and light constant domains (41 7753). DNA
coding for the BH10 clade B HIV-1 gag p24 (NIH AIDS
Reference Reagent), amino acid 133-363 was cloned in-frame
into the carboxyl terminus of the heavy chains. Fusion HIV gag
p24 mAbs were produced by transient transfection (calcium-
phosphate) in 293 T cells in serum-free DMEM supplemented
with Nutridoma SP (Roche, Indianapolis, IN), purified on
protein G columns (GE Healthcare), and characterized by
SDS/PAGE and Western blot analysis (41). The integrity of the
mAbs was further characterized on immature DCs by FACS
using a phycoerythrin-conjugated goat -mouse IgG (Jackson
ImmunoResearch, West Grove, PA).
HIV gag Peptides. A library of overlapping (staggered by 4 aa)
15-mer peptides was obtained from the NIH AIDS Reference
Reagent Program. This library contained 55 peptides, covering
the entire gag p24 region (amino acids 133–363), that were
pooled and resuspended at 1 mg/ml of each peptide in 100%
DMSO. The library was also divided into five pools of 9–12
single peptides, spanning amino acids 133–183 (pool I), amino
acids 173–231 (pool II), amino acids 221–279 (pool III), amino
acids 269–327 (pool IV), and amino acids 317–363 (pool V) of
gag p24.
Expansion of Antigen-Specific T Cells in PBMCs. PBMCs were labeled
with 1 M CFSE (Molecular Probes, Eugene, OR), and 106 cells
were plated in 96-well deep-well plates in 500 l of RPMI 5% HS.
The cells were left unstimulated (negative control) or stimulated
with SEB (Sigma, St. Louis, MO) at 20 ng/ml (positive control),
HIV gag peptides at 2 g/ml, and with DEC p24, DC-SIGN p24,
MMR p24, and control Ig p24 at 0.1 to 10 g/ml. After 6–7 d of
culture, samples were restimulated for 8 h with or without p24
peptides (2 g/ml), either all 55 peptides or individual pools of
peptides, in the presence of 0.5 g/ml of CD28 and CD49d
(clones L293 and L25; BD Biosciences), adding BFA (Sigma) at 10
g/ml for the last 6 h to block cytokine secretion. The cells were
fixed, permeabilized and stained with a combination of fluoro-
chrome-conjugated antibodies: perCP-CD3, APC-CD8, and PE-
IFN or its respective isotype control. Cells were analyzed on a
FACS-Calibur II using CELLQuest software, collecting 50,000–
100,000 high-CD3 events. Most of the data were displayed as
two-color dot plots (FL1 vs. FL2) to measure CFSE dilution and
IFN production in CD3 CD8 cells.
Expansion of Antigen-Specific T Cells in DC/T Cell Coculture. To
directly assess the function of DCs in presenting the gag fusion
mAbs, we used, in parallel to the PBMCs assay above, monocyte-
derived DCs. Immature cells at day 5 of monocyte culture in
GM-CSF and IL-4 were collected and pulsed overnight with
medium, p24 peptides (2 g/ml), or DEC p24, DC-SIGN p24,
MMR p24, and control Ig p24 at 1 g/ml. The antigen-pulsed
DCs were matured by adding -irradiated CD40L-expressing
cells (kindly provided by J. Banchereau, Dallas, TX) at a ratio of
1:5 (CD40L:DC) for 48 h. CD40 ligation enhances cross-
presentation by DCs (53). Syngeneic CD14 cells were thawed,
rested for 2 h at 37°C before CFSE labeling and plating in 48-well
plates at 1.5 to 2  106 per ml and cultured with the antigen-
pulsed mature DCs at a DC/T ratio 1:30. The cocultures were
incubated at 37°C for 6–7 d. Each sample was then restimulated
for the last 8 h with or without p24 peptides (2 g/ml) in the
presence of costimulator mAbs (0.5 g/ml). Cells were analyzed
for CFSE dilution and IFN secretion as above. Where neces-
sary, data comparing the frequency of CFSElow proliferating,




Active p24 peptide in pool HLA class I
No. Sequence A1 A2 B1 B2 C1 C2
LB02 I 10 FVEKAFSPEVIPMFSAL 2010 3201 4001 5701 0304 0602
LB03 III 5 AGTTSTLQEQIGWMT 0202 3601 5301 5701 0401 0401
6 STLQEQIGWMTNNPP
LB04 I 10 EKAFSPEVIPMFSAL 0301 1101 3501 5701 0401 0401




LB06 III 9 NPPIPVGEIYKRWII 2301 7401 0801 1801 0304 0202
10 PVGEIYKRWIILGLN
LB07 III 11 IYKRWWIILGLNKIVR 0301 1101 0702 0733 0702 0704
V 8 EMMTACQGVGGPGHK
9 ACQGVGGPGHKARVL
LB10 II 10 AAEWDRLHPVHAGPI 2402 6601 1503 3501 0401 0401
11 DRLHPVHAGPIAPGQ
LB11 II 9 INEEAAEWDRLHPVH 3201 3201 1402 4002 0802 0202
10 AAEWDRLHPVHAGPI
As in Table 1 and Fig. 4, gag peptides were identified that were recognized by CD8 T cells after proliferation in response to DEC
p24. We first identified a pool of gag peptides (column 2), and then the peptide pool was broken down into individual peptides to
identify the optimal mimetope (columns 3 and 4). After typing for HLA class I alleles at HLA-A, B, and C loci for each patient, we were
able to identify from the Los Alamos database (www.hiv.lanl.gov/content/index) known peptide sequences that are presented on a
corresponding HLA product in bold and, in one case (patient LB07), a second peptide (underlined).









































IFN secreting, CD3 CD8 T cells were compared by using a
paired two-tail t test.
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52. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B,
Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) J Exp Med
180:83–93.
53. Delamarre L, Holcombe H, Mellman I (2003) J Exp Med 198:111–122.
1294  www.pnas.orgcgidoi10.1073pnas.0610383104 Bozzacco et al.
D
ow
nl
oa
de
d 
at
 R
oc
ke
fe
lle
r 
U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
A
ug
us
t 1
7,
 2
02
0 
